U.S. Genetic Testing Market

U.S. Genetic Testing Market Size (2024 to 2029) 

The size of the genetic testing market in the United States is expected to showcase a remarkable CAGR from 2024 to 2029. 

The growing incidence of genetic disorders across the U.S. is one of the major factors propelling the U.S. genetic testing market. Cystic fibrosis, a prevalent and fatal genetic disorder in the U.S., affects approximately 30,000 individuals and causes blockages in the lungs, leading to infections. The availability of genetic drugs has enabled personalized treatment options for these patients, facilitating the cure or prevention of their ailments. Other commonly observed genetic disorders in the population include albinism, Angelman syndrome, Charcot-Marie tooth disease and Down syndrome among others.

The demand for genetic testing has grown significantly in recent years owing to the growing cancer patient population and growing number of fatalities in the U.S. and this trend is likely to fuel in the coming years and contribute to the U.S. market growth. Genetic testing helps in assessing the likelihood of developing cancer during one's lifetime by examining alterations in genes, chromosomes and proteins. Genetic testing is available for various types of cancers including but not limited to ovarian, breast, thyroid, colon, melanoma, and stomach cancers.

The rapid adoption of advancements of cutting-edge devices in this field is another major attribute fuelling the growth rate of the U.S. market. In response to the growing incidence of chronic illnesses, researchers and manufacturers are channeling their efforts toward creating sophisticated genetic testing kits that provide precise results. Furthermore, governmental backing, private and public sector investments, and reimbursement policies are other driving forces behind the heightened demand for genetic testing.

The growth of the market in the United States is further driven by continuous advancements in the healthcare sector and increasing healthcare expenditure. Some leading insurance companies are requesting individuals to provide their genetic information to apply for life insurance. Moreover, the rising approval of various genetic tests for a wide range of medical conditions is further fueling the demand for genetic testing in the country. In the United States, genetic testing for newborns is typically conducted within 48 hours of birth, with a sample taken from the baby and analyzed for approximately 50 diseases, including sickle cell disease, phenylketonuria, and hypothyroidism. Annually, about 4 million newborns undergo genetic testing, which aids in detecting the possibility of developing chronic illnesses and helps prevent health issues throughout their lifetime. In Columbia City, Newborn Screening is conducted to detect, diagnose, and treat every newborn whose test results are positive for genetic disorders. California also commands a significant share of the market due to the frequent introduction of new programs in the state. In 2022, the California Prenatal Screening (PNS) program was launched, which can be performed on pregnant women throughout their pregnancy starting from ten weeks.

On the other hand, the high cost of the genetic testing process, data security and privacy concerns hamper the growth of the U.S. genetic market growth. Details about the patient may be misused may be hacked and cause several problems. In addition, poor awareness of genetic testing among the U.S. population, lack of skilled professionals at research centers, and strict regulations further impede the U.S. market growth. Some of the other limitations of genetic testing are if a person gets a positive result in genetic testing, a person will suffer from depression, anxiety, and guilty and become skin. False result in genetic testing also challenges market growth.

MARKET SEGMENTATION:

By Type:

• Carrier Testing
• Prenatal Testing
• Diagnostic Testing
• Neonatal Testing

By Application:

• Cancer Testing
• Pharmacogenomics Testing
• Prenatal Testing
• Predisposition Testing

KEY MARKET PLAYERS:

Companies such as Abbott Laboratories, Roche Molecular Diagnostics, Inc., Abbott Molecular Inc., Auto Genomics, Inc., Celera Group, ELITech Group, BioRad Laboratories, PerkinElmer Inc., Roche Diagnostics Corp., Quest Diagnostics Inc., Transgenomic Inc., and Applied Biosystems, Inc. are the leading companies in the U.S. Genetic Testing Market.